Global Rilonacept Drugs Market
Global Rilonacept Drugs Market

Rilonacept Drugs Comprehensive Study by Application (Pediatric, Adult, Geriatric), Treatment (Familial Cold Urticaria Syndrome (FCUS), Muckle-Wells Syndrome (MWS), Neonatal Onset Multisystem Inflammatory Disease (NOMID)), Distribution Channel (Hospital Pharma, Specialty Pharma Retail Stores) Players and Region - Global Market Outlook to 2026

Rilonacept Drugs Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Apr 2021 Edition 220 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Rilonacept Drugs Market Overview:
Rilonacept is a dimeric fusion protein made up of the extracellular ligand-binding domains of the human interleukin-1 receptor segment (IL-1RI) and IL-1 receptor accessory protein (IL-1RAcP) connected in-line to the Fc portion of human IgG1. Rilonacept-based drug ARCALYST is a prescription drug known as an interleukin-1 (IL-1) antagonist. Cryopyrin-associated intermittent syndromes (CAPS), such as familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome, are treated with this drug (MWS). ARCALYST comes in single-use 20-mL glass vials of a sterile, off-white lyophilized powder. ARCALYST should be reconstituted with 2.3 mL of Sterile Water for Injection per vial. Patients taking ARCALYST have developed serious illnesses, including life-threatening infections and death. Rilonacept is a drug that is used to treat a variety Drugs may have an effect on the immune system, reducing the ability to combat pathogens.

Growth Drivers
  • Prevalence of Familial cold autoinflammatory syndrome (FCAS)
  • Rising Geriatric Population

Market Trends
  • Technical Progress in Medical Industry

Roadblocks
  • Side Effects and Adverse Reactions

Opportunities
  • Unexplored Markets

Challenges
  • Regulatory Approval


Competitive Landscape:
The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth.
Some of the key players profiled in the report are Kiniksa Pharmaceuticals, Ltd. (Bermuda) and Regeneron Pharmaceuticals (United States). Considering Market by Treatment, the sub-segment i.e. Familial Cold Urticaria Syndrome (FCUS) will boost the Rilonacept Drugs market. Considering Market by Distribution Channel, the sub-segment i.e. Hospital Pharma will boost the Rilonacept Drugs market.

On 18th March, 2021 - Received US Food and Drug Administration (FDA) Clearance for ARCALYST (Rilonacept) for the Treatment of Recurrent Pericarditis and Reduction in Risk of Recurrence in Adults and Children 12 Years and Older.

European Medicines Agency, EU/3/07/456; Revoked - Orphan Designation Granted to Regeneron UK Ltd., For Its Rilonacept Drug Was Withdrawn by the European Commission on 24 October 2012. The Drug Is No Longer Valid for Sale Across EU. and United States, Food and Drug Administration “ARCALYST/Rilonacept” Label; Provides a Comprehensive List of Procedures Regarding the Usage, Indications and Dosage Requirements Based on the Patient Profile of ARCALYST Injections Across US.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Rilonacept Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Rilonacept Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants and Investors, API Providers, Rilonacept Drugs Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Application
  • Pediatric
  • Adult
  • Geriatric
By Treatment
  • Familial Cold Urticaria Syndrome (FCUS)
  • Muckle-Wells Syndrome (MWS)
  • Neonatal Onset Multisystem Inflammatory Disease (NOMID)

By Distribution Channel
  • Hospital Pharma
  • Specialty Pharma Retail Stores

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Familial cold autoinflammatory syndrome (FCAS)
      • 3.2.2. Rising Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Regulatory Approval
    • 3.4. Market Trends
      • 3.4.1. Technical Progress in Medical Industry
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Rilonacept Drugs, by Application, Treatment, Distribution Channel and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Rilonacept Drugs (Value)
      • 5.2.1. Global Rilonacept Drugs by: Application (Value)
        • 5.2.1.1. Pediatric
        • 5.2.1.2. Adult
        • 5.2.1.3. Geriatric
      • 5.2.2. Global Rilonacept Drugs by: Treatment (Value)
        • 5.2.2.1. Familial Cold Urticaria Syndrome (FCUS)
        • 5.2.2.2. Muckle-Wells Syndrome (MWS)
        • 5.2.2.3. Neonatal Onset Multisystem Inflammatory Disease (NOMID)
      • 5.2.3. Global Rilonacept Drugs by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharma
        • 5.2.3.2. Specialty Pharma Retail Stores
      • 5.2.4. Global Rilonacept Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Rilonacept Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Kiniksa Pharmaceuticals, Ltd. (Bermuda)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Regeneron Pharmaceuticals (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
  • 7. Global Rilonacept Drugs Sale, by Application, Treatment, Distribution Channel and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Rilonacept Drugs (Value)
      • 7.2.1. Global Rilonacept Drugs by: Application (Value)
        • 7.2.1.1. Pediatric
        • 7.2.1.2. Adult
        • 7.2.1.3. Geriatric
      • 7.2.2. Global Rilonacept Drugs by: Treatment (Value)
        • 7.2.2.1. Familial Cold Urticaria Syndrome (FCUS)
        • 7.2.2.2. Muckle-Wells Syndrome (MWS)
        • 7.2.2.3. Neonatal Onset Multisystem Inflammatory Disease (NOMID)
      • 7.2.3. Global Rilonacept Drugs by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharma
        • 7.2.3.2. Specialty Pharma Retail Stores
      • 7.2.4. Global Rilonacept Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Rilonacept Drugs: by Application(USD Million)
  • Table 2. Rilonacept Drugs Pediatric , by Region USD Million (2015-2020)
  • Table 3. Rilonacept Drugs Adult , by Region USD Million (2015-2020)
  • Table 4. Rilonacept Drugs Geriatric , by Region USD Million (2015-2020)
  • Table 5. Rilonacept Drugs: by Treatment(USD Million)
  • Table 6. Rilonacept Drugs Familial Cold Urticaria Syndrome (FCUS) , by Region USD Million (2015-2020)
  • Table 7. Rilonacept Drugs Muckle-Wells Syndrome (MWS) , by Region USD Million (2015-2020)
  • Table 8. Rilonacept Drugs Neonatal Onset Multisystem Inflammatory Disease (NOMID) , by Region USD Million (2015-2020)
  • Table 9. Rilonacept Drugs: by Distribution Channel(USD Million)
  • Table 10. Rilonacept Drugs Hospital Pharma , by Region USD Million (2015-2020)
  • Table 11. Rilonacept Drugs Specialty Pharma Retail Stores , by Region USD Million (2015-2020)
  • Table 12. South America Rilonacept Drugs, by Country USD Million (2015-2020)
  • Table 13. South America Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 14. South America Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 15. South America Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 16. Brazil Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 17. Brazil Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 18. Brazil Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 19. Argentina Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 20. Argentina Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 21. Argentina Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 22. Rest of South America Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 23. Rest of South America Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 24. Rest of South America Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 25. Asia Pacific Rilonacept Drugs, by Country USD Million (2015-2020)
  • Table 26. Asia Pacific Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 27. Asia Pacific Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 28. Asia Pacific Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 29. China Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 30. China Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 31. China Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 32. Japan Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 33. Japan Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 34. Japan Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 35. India Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 36. India Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 37. India Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 38. South Korea Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 39. South Korea Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 40. South Korea Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 41. Taiwan Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 42. Taiwan Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 43. Taiwan Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 44. Australia Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 45. Australia Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 46. Australia Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 50. Europe Rilonacept Drugs, by Country USD Million (2015-2020)
  • Table 51. Europe Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 52. Europe Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 53. Europe Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 54. Germany Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 55. Germany Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 56. Germany Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 57. France Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 58. France Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 59. France Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 60. Italy Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 61. Italy Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 62. Italy Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 63. United Kingdom Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 64. United Kingdom Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 65. United Kingdom Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 66. Netherlands Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 67. Netherlands Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 68. Netherlands Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 69. Rest of Europe Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 70. Rest of Europe Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 71. Rest of Europe Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 72. MEA Rilonacept Drugs, by Country USD Million (2015-2020)
  • Table 73. MEA Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 74. MEA Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 75. MEA Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 76. Middle East Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 77. Middle East Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 78. Middle East Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 79. Africa Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 80. Africa Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 81. Africa Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 82. North America Rilonacept Drugs, by Country USD Million (2015-2020)
  • Table 83. North America Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 84. North America Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 85. North America Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 86. United States Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 87. United States Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 88. United States Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 89. Canada Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 90. Canada Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 91. Canada Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 92. Mexico Rilonacept Drugs, by Application USD Million (2015-2020)
  • Table 93. Mexico Rilonacept Drugs, by Treatment USD Million (2015-2020)
  • Table 94. Mexico Rilonacept Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Rilonacept Drugs: by Application(USD Million)
  • Table 98. Rilonacept Drugs Pediatric , by Region USD Million (2021-2026)
  • Table 99. Rilonacept Drugs Adult , by Region USD Million (2021-2026)
  • Table 100. Rilonacept Drugs Geriatric , by Region USD Million (2021-2026)
  • Table 101. Rilonacept Drugs: by Treatment(USD Million)
  • Table 102. Rilonacept Drugs Familial Cold Urticaria Syndrome (FCUS) , by Region USD Million (2021-2026)
  • Table 103. Rilonacept Drugs Muckle-Wells Syndrome (MWS) , by Region USD Million (2021-2026)
  • Table 104. Rilonacept Drugs Neonatal Onset Multisystem Inflammatory Disease (NOMID) , by Region USD Million (2021-2026)
  • Table 105. Rilonacept Drugs: by Distribution Channel(USD Million)
  • Table 106. Rilonacept Drugs Hospital Pharma , by Region USD Million (2021-2026)
  • Table 107. Rilonacept Drugs Specialty Pharma Retail Stores , by Region USD Million (2021-2026)
  • Table 108. South America Rilonacept Drugs, by Country USD Million (2021-2026)
  • Table 109. South America Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 110. South America Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 111. South America Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 112. Brazil Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 113. Brazil Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 114. Brazil Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 115. Argentina Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 116. Argentina Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 117. Argentina Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 118. Rest of South America Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 119. Rest of South America Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 120. Rest of South America Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 121. Asia Pacific Rilonacept Drugs, by Country USD Million (2021-2026)
  • Table 122. Asia Pacific Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 123. Asia Pacific Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 124. Asia Pacific Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 125. China Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 126. China Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 127. China Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 128. Japan Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 129. Japan Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 130. Japan Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 131. India Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 132. India Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 133. India Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 134. South Korea Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 135. South Korea Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 136. South Korea Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 137. Taiwan Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 138. Taiwan Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 139. Taiwan Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 140. Australia Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 141. Australia Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 142. Australia Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 143. Rest of Asia-Pacific Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 144. Rest of Asia-Pacific Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 145. Rest of Asia-Pacific Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 146. Europe Rilonacept Drugs, by Country USD Million (2021-2026)
  • Table 147. Europe Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 148. Europe Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 149. Europe Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 150. Germany Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 151. Germany Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 152. Germany Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 153. France Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 154. France Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 155. France Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 156. Italy Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 157. Italy Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 158. Italy Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 159. United Kingdom Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 160. United Kingdom Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 161. United Kingdom Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 162. Netherlands Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 163. Netherlands Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 164. Netherlands Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 165. Rest of Europe Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 166. Rest of Europe Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 167. Rest of Europe Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 168. MEA Rilonacept Drugs, by Country USD Million (2021-2026)
  • Table 169. MEA Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 170. MEA Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 171. MEA Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 172. Middle East Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 173. Middle East Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 174. Middle East Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 175. Africa Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 176. Africa Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 177. Africa Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 178. North America Rilonacept Drugs, by Country USD Million (2021-2026)
  • Table 179. North America Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 180. North America Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 181. North America Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 182. United States Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 183. United States Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 184. United States Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 185. Canada Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 186. Canada Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 187. Canada Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 188. Mexico Rilonacept Drugs, by Application USD Million (2021-2026)
  • Table 189. Mexico Rilonacept Drugs, by Treatment USD Million (2021-2026)
  • Table 190. Mexico Rilonacept Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 191. Research Programs/Design for This Report
  • Table 192. Key Data Information from Secondary Sources
  • Table 193. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Rilonacept Drugs: by Application USD Million (2015-2020)
  • Figure 5. Global Rilonacept Drugs: by Treatment USD Million (2015-2020)
  • Figure 6. Global Rilonacept Drugs: by Distribution Channel USD Million (2015-2020)
  • Figure 7. South America Rilonacept Drugs Share (%), by Country
  • Figure 8. Asia Pacific Rilonacept Drugs Share (%), by Country
  • Figure 9. Europe Rilonacept Drugs Share (%), by Country
  • Figure 10. MEA Rilonacept Drugs Share (%), by Country
  • Figure 11. North America Rilonacept Drugs Share (%), by Country
  • Figure 12. Global Rilonacept Drugs share by Players 2020 (%)
  • Figure 13. BCG Matrix for key Companies
  • Figure 14. Kiniksa Pharmaceuticals, Ltd. (Bermuda) Revenue, Net Income and Gross profit
  • Figure 15. Kiniksa Pharmaceuticals, Ltd. (Bermuda) Revenue: by Geography 2020
  • Figure 16. Regeneron Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 17. Regeneron Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 18. Global Rilonacept Drugs: by Application USD Million (2021-2026)
  • Figure 19. Global Rilonacept Drugs: by Treatment USD Million (2021-2026)
  • Figure 20. Global Rilonacept Drugs: by Distribution Channel USD Million (2021-2026)
  • Figure 21. South America Rilonacept Drugs Share (%), by Country
  • Figure 22. Asia Pacific Rilonacept Drugs Share (%), by Country
  • Figure 23. Europe Rilonacept Drugs Share (%), by Country
  • Figure 24. MEA Rilonacept Drugs Share (%), by Country
  • Figure 25. North America Rilonacept Drugs Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Kiniksa Pharmaceuticals, Ltd. (Bermuda)
  • Regeneron Pharmaceuticals (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation